Kintara Therapeutics FY2023 net loss $14.6M, cash $1.5M; VAL-083 data expected by year-end

TuHURA Biosciences, Inc./NV

Net loss $14.6M ($9.27/share) vs $22.7M ($25.80) in FY2022; R&D fell to $9.3M from $15.2M.
Cash and equivalents $1.5M at June 30, 2023, down from $11.8M; working capital $188K.
Awarded $2.0M NIH SBIR grant for REM-001; first patient in 15-patient study expected Q4 2023.
Top-line data from VAL-083 GBM AGILE registrational study anticipated before end of calendar 2023.
General and administrative costs decreased to $5.5M from $7.5M due to reduced staffing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TuHURA Biosciences, Inc./NV reported the fiscal year ended June 30, 2023 results: net income a net loss of approximately $14.6 million, or $9.27 per share, EPS $9.27 per share.

Period: the fiscal year ended June 30, 2023
Net income: a net loss of approximately $14.6 million, or $9.27 per share
EPS: $9.27 per share
Result: reported results

Exact text from the filing

For the year ended June 30, 2023, Kintara reported a net loss of approximately $14.6 million, or $9.27 per share, compared to a net loss of approximately $22.7 million, or $25.80 per share, for the year ended June 30, 2022.

View on SEC.gov

9 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-048593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.